Originally published on Technavio:Exploring the Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Forecast and Insights

Technavio presents an in-depth analysis of the Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics market, projecting trends from 2023 to 2027. Published in February 2023, this 166-page report provides comprehensive insights into market dynamics, growth drivers, challenges, and customer landscapes.

Key Highlights: Snapshot and Methodology

Our report begins with a snapshot of the DLBCL Therapeutics market, detailing pages, publication information, and SKU. Employing robust methodology ensures the accuracy and reliability of our forecasts, enabling stakeholders to make informed decisions.

Market Forecast: Growth Drivers and Trends

The DLBCL Therapeutics market is projected to increase by USD 2,061.88 million between 2022 and 2027, growing at a CAGR of 7.96%. Market growth hinges on various factors, including the growing geriatric population, increasing incidence, and rising approval of therapeutics for patients with relapsed or refractory DLBCL.

Market Dynamics and Customer Landscape

The increasing approval of therapeutics for patients with relapsed or refractory DLBCL significantly drives market growth, although factors such as the high cost of treatment may impede growth. Our researchers analyzed data with 2022 as the base year, along with key drivers, trends, and challenges, facilitating companies in refining marketing strategies to gain a competitive advantage.

Key Market Drivers

The increasing approval of therapeutics for patients with relapsed or refractory DLBCL is significantly driving market growth. Market players focus on regulatory approvals for such therapeutics, fueling market growth. For instance, Bristol Myers Squibb received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), a CAR T-cell therapy indicated for various lymphoma types. Similarly, ADC Therapeutics' Biologics License Application (BLA) for loncastuximab tesirine (Lonca) was accepted by the US FDA, driving market growth during the forecast period.

Significant Market Trend

Technological advances emerge as a trend in market growth. Companies focus on developing new technologies and innovative therapies to address challenges in DLBCL treatment. CAR T-cell therapy, gene therapy, companion diagnostics, and personalized medicines are rapidly developed, enhancing product efficacy and effectiveness in treating DLBCL. Players like Novartis and Gilead focus on CAR T-cell therapy and gene therapy, fueling market growth.

Major Challenge

The high cost of DLBCL treatment poses a significant challenge, hindering market growth. Treatment costs associated with DLBCL, including chemotherapy and biologics, are substantial. Recurrent or relapsed DLBCL cases further escalate treatment expenses, impacting patient affordability. Moreover, inadequate drug distribution networks in developing economies increase distribution costs, hindering market growth during the forecast period.

Key Market Customer Landscape

Our report includes the adoption lifecycle of the market, focusing on adoption rates and purchase criteria across regions, aiding companies in developing growth strategies.

Major Players in the DLBCL Therapeutics Market

Companies implement various strategies to enhance market presence, including alliances, partnerships, and product launches. Amgen Inc., AbbVie Inc., Bristol Myers Squibb Co., Novartis AG, and Pfizer Inc. are among the major players analyzed in our report.

Fastest-Growing Segment

The hospital pharmacy segment is expected to witness significant growth during the forecast period. Hospital pharmacies play a crucial role in managing DLBCL therapeutics, from storage to dispensing. DLBCL therapeutics are often administered in clinical settings, with hospital pharmacists overseeing treatment management, contributing to segment growth.

To Learn deeper into this report , View Sample PDF

Understanding key trends, drivers, and challenges is crucial for stakeholders to capitalize on growth opportunities in the DLBCL Therapeutics market. Our report offers comprehensive insights to guide strategic decision-making in this dynamic market landscape.

The report forecasts revenue growth at global, regional, and country levels, providing insights into trends and opportunities from 2017 to 2027.

For more information please contact.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com/